General Information |
| Organization Type - Primary: |
Private Sector |
| Organization Type - Secondary: |
Company |
| Is your organization legally registered in your country: |
Yes |
| Organization Reach: |
International |
| Organization Description: |
Vaccine Research and Development - Developing vaccines against infectious disease targets using proprietary ImmBioVax vaccine technology platform that give multi-subunit vaccines that elicit polyclonal cellular and humoral immunity.
Developing multi-subunit TB vaccine, initially to boost BCG, that can be used in HIV positive people |
| |
| Total number of staff in your organization: |
11 - 25 |
| Number of full-time staff who are directly involved with TB: |
1 - 5 |
| Number of part-time staff who are directly involved with TB: |
1 - 5 |
| Number of volunteers who are directly involved with TB: |
0 |
| |
| What is your organization's annual budget (USD) dedicated to TB? |
$100,001-$500,000 |
| How did you hear about the Stop TB Partnership: |
Involvement in TB control provision |
| Why do you wish join the Stop TB Partnership: |
Involvement in Stop TB Working Groups |
| |
| Are you a member of a Stop TB national partnership: |
No |
| Are you in contact with your national TB programme: |
No |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| Development of a TB vaccine |
| |
Geographical Reach |
| Which country is your headquarters located in: |
United Kingdom of Great Britain and Northern Ireland |
| Which WHO region is the main focus of your work: |
European |
Which countries do you do operate in:
(This includes countries you are conducting activities in) |
United Kingdom of Great Britain and Northern Ireland
|
